Arkolith/Insider Trading/ORIC/Form 4

Heyman Richard A.

DirectorOric Pharmaceuticals, Inc. (ORIC) · full profile →Form 4 · filed Jan 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$80K
Net Open-Market Flow
-$80K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 16, 2026Sell(S)3K$12.00$38K213K
Jan 16, 2026Sell(S)4K$12.00$42K42K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001584759-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML